Advert - Astellas UK

Astellas UK made a voluntary admission about its oversight of and materials produced for two patient support programmes related to Betmiga (mirabegron) and Vesicare (solifenacin succinate), and it was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.

Clause 7.2 - Providing inaccurate and out-of-date material.

Clause 7.9 - Providing material that did not accurately reflect up-to-date information on possible side effects.

Clause 7.11 - Describing a medicine as new for more than twelve months.

Clause 9.1 - Failing to maintain high standards.

Clause 14.3 - Failing to certify material.

Clause 14.5 - Using material beyond two years without re-certification.

Clause 21 - Failing to disclose transfers of value on the ABPI central platform.

Clause 24.1 - Failing to disclose transfers of value on the ABPI central platform.

The Code of Practice Panel reported Astellas UK to the Code of Practice Appeal Board, which publicly reprimanded Astellas UK. The public reprimand appears on the front cover of the PMCPA May Code of Practice Review which, with the interim case report, is available at www.pmcpa.org.uk.

Advert - May 2017